Integrated Biopharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supple… Read more
Integrated Biopharma Inc (INBP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.063x
Based on the latest financial reports, Integrated Biopharma Inc (INBP) has a cash flow conversion efficiency ratio of 0.063x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.30 Million) by net assets ($20.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Integrated Biopharma Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Integrated Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Integrated Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integrated Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
APPLIED MATERIALS (AP2.SG)
STU:AP2
|
0.127x |
|
AVI Global Trust PLC
LSE:AGT
|
0.002x |
|
Swiftmerge Acquisition Corp. Warrants
NASDAQ:IVCPW
|
0.070x |
|
Metalex Ventures Ltd
PINK:MXTLF
|
-0.095x |
|
North Stawell Minerals Ltd
AU:NSM
|
0.010x |
|
Infracommerce CXaaS S.A
SA:IFCM3
|
-0.075x |
|
STRYKER - Dusseldorf Stock Exchang
DU:SYK
|
0.073x |
|
Fertoz Ltd
AU:FTZ
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Integrated Biopharma Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Integrated Biopharma Inc from 2000 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $20.32 Million | $2.06 Million | 0.102x | +107.35% |
| 2024-06-30 | $19.24 Million | $943.00K | 0.049x | -24.96% |
| 2023-06-30 | $18.86 Million | $1.23 Million | 0.065x | -70.34% |
| 2022-06-30 | $18.57 Million | $4.09 Million | 0.220x | +3.51% |
| 2021-06-30 | $14.33 Million | $3.05 Million | 0.213x | -3.59% |
| 2020-06-30 | $6.07 Million | $1.34 Million | 0.221x | +27.37% |
| 2019-06-30 | $1.89 Million | $328.00K | 0.173x | +177.67% |
| 2018-06-30 | $-5.24 Million | $1.17 Million | -0.223x | -233.15% |
| 2017-06-30 | $-5.93 Million | $397.00K | -0.067x | -193.87% |
| 2016-06-30 | $-8.33 Million | $-594.00K | 0.071x | +488.10% |
| 2015-06-30 | $-9.32 Million | $-113.00K | 0.012x | +106.56% |
| 2014-06-30 | $-10.15 Million | $1.88 Million | -0.185x | -257.36% |
| 2011-06-30 | $-7.70 Million | $398.00K | -0.052x | -128.45% |
| 2006-06-30 | $25.73 Million | $4.68 Million | 0.182x | -50.26% |
| 2002-06-30 | $7.58 Million | $2.77 Million | 0.365x | -43.18% |
| 2000-06-30 | $6.37 Million | $4.10 Million | 0.643x | -- |